Live Database of Fundraising Deeptech Startups in Europe
Explore Now

Today's Picks

Most Recent

Lendurai raises €5.6M Seed, for autonomous UAV systems in GPS-denied environments

Quick Facts🗂️ Company: Lendurai Website: https://lendurai.com LinkedIn: https://www.linkedin.com/company/lendurai/ Location: Tallinn, Estonia Funding Round: Seed Amount Raised: €5.6M Lead Investor(s): Expeditions Fund Other Investors: Vsquared, HCVC, Lemonade Stand All Investors: Expeditions Fund, HCVC, Lemonade Stand, Vsquared Total Funding to Date: €5.6M Founded: 2024 Sector: Defense Technology, Autonomous UAV Systems Company...

Most Recent

Trending

Important

United Robotics Group acquires Robotnik Automation, focused on AMRs & manipulators

Spain-based Robotnik Automation provides "mobile service robotics technology". The startup is focused on the development, manufacture & commercialization of AMRs as well "mobile manipulators" for different applications in both industrial & academic fields: inspection, inventory, security & logistics. Founded in 2002 by Robert Guzman (CEO) & Rafael Lopez (COO), the company has sold <5000 robots in 50 countries around the world (incl. Korea, Japan, China, Singapore, USA, France, Germany, Italy) & participated in <60 European R&D projects. Robotnik Automation has its own R&D department & a team of <70 multidisciplinary employees. One notable robot developed by them is called SUMMIT-XL, which is used for inspection applications in tunnels, remote substations, agricultural fields, shipbuilding & railway...

Dxcover raises €10.5m Series A, for liquid biopsy platform to detect cancer

UK-based, Dxcover (previously Clinspec Diagnostics) is a clinical-stage diagnostics company. The startup has developed a liquid biopsy platform - powered by “attenuated total reflectance, fourier transform infrared spectroscopy” “of pan-omic biomarkers” - which analyzes patient blood samples (with the help of AI) to detect the presence (or absence) of cancer. It generates compelling clinical data with high accuracy detection (80-90%) of Stage I & II brain tumors, particularly Glioblastoma Multiforme (the most aggressive type). The firm has also published data with “exceptional potential” on detecting pancreatic cancer as well as 6 other types (lung, colon, breast, prostate, ovarian & kidney) (the 8-types combined, account for 65% of the global cancer burden). Various patents have already...

More from categories